151 related articles for article (PubMed ID: 36523775)
21. An empirical study of the impact of generic drug competition on drug market prices in China.
Yina C; Pengcheng L; Haomiao N; Yang C
Front Public Health; 2023; 11():1146531. PubMed ID: 37304112
[TBL] [Abstract][Full Text] [Related]
22. The Effect of Market Competition on the Price of Topical Eye Drops.
Watane A; Kalavar M; Reyes J; Yannuzzi NA; Sridhar J
Semin Ophthalmol; 2022 Jan; 37(1):42-48. PubMed ID: 33780301
[TBL] [Abstract][Full Text] [Related]
23. The Evolution of Supply and Demand in Markets for Generic Drugs.
Frank RG; McGuire TG; Nason I
Milbank Q; 2021 Sep; 99(3):828-852. PubMed ID: 34075623
[TBL] [Abstract][Full Text] [Related]
24. Who initiates price competition when generic entrants are introduced into the South Korean pharmaceutical market?
Son KB
Front Public Health; 2022; 10():934161. PubMed ID: 36187703
[TBL] [Abstract][Full Text] [Related]
25. A comparative analysis of generics markets in five European countries.
Garattini L; Tediosi F
Health Policy; 2000 Apr; 51(3):149-62. PubMed ID: 10720685
[TBL] [Abstract][Full Text] [Related]
26. Marketing and Pricing Strategies of Blockbuster Drugs in the South Korean Market: A 15-Year Retrospective Cohort Study for Choline Alfoscerate.
Park J; Bae S; Lee TJ; Son KB
Front Pharmacol; 2020; 11():232. PubMed ID: 32210817
[TBL] [Abstract][Full Text] [Related]
27. Novel methodology for pharmaceutical expenditure forecast.
Vataire AL; Cetinsoy L; Aballéa S; Rémuzat C; Urbinati D; Kornfeld Å; Mzoughi O; Toumi M
J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226843
[TBL] [Abstract][Full Text] [Related]
28. Do higher-priced generic medicines enjoy a competitive advantage under reference pricing?
Puig-Junoy J
Appl Health Econ Health Policy; 2012 Nov; 10(6):441-51. PubMed ID: 22900924
[TBL] [Abstract][Full Text] [Related]
29. Global Barriers to Accessing Off-Patent Endocrine Therapies: A Renaissance of the Orphan Disease?
de Silva NL; Dissanayake H; Kalra S; Meeran K; Somasundaram NP; Jayasena CN
J Clin Endocrinol Metab; 2024 Apr; 109(5):e1379-e1388. PubMed ID: 37846800
[TBL] [Abstract][Full Text] [Related]
30. High prices for generics in Australia - more competition might help.
Bulfone L
Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
[TBL] [Abstract][Full Text] [Related]
31. The timelines for the price and reimbursement authorization in Italy 2018-2020.
Gallo V; Alessi E; Montilla S; Altamura G; Traversa G; Trotta F
Front Med (Lausanne); 2022; 9():1055359. PubMed ID: 36619645
[TBL] [Abstract][Full Text] [Related]
32. Effect of Patent Expiry on the Performance of Innovator Multinational Pharmaceutical Companies in a Low Middle Income Country.
Khalil F; Onyango JO
Front Med Technol; 2022; 4():783460. PubMed ID: 35445207
[TBL] [Abstract][Full Text] [Related]
33. Generic drugs: Review and experiences from South India.
Mathew P
J Family Med Prim Care; 2015; 4(3):319-23. PubMed ID: 26286613
[TBL] [Abstract][Full Text] [Related]
34. Generic medicine pricing in Europe: current issues and future perspective.
Simoens S
J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
[TBL] [Abstract][Full Text] [Related]
35. Use of budget savings from patent expiration of cancer drugs to improve affordability and accessibility.
Lee SM; Kim HJ; Suh D; Joung KI; Kim ES; Back HJ; Kwon JY; Park MJ; Suh DC
BMC Health Serv Res; 2021 Feb; 21(1):126. PubMed ID: 33549099
[TBL] [Abstract][Full Text] [Related]
36. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
Li DG; Joyce C; Mostaghimi A
JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
[TBL] [Abstract][Full Text] [Related]
37. [Competition between branded and generic drugs in Austria: evidence from the market for ACE inhibitors].
Mahlich JC; Stadler I
Gesundheitswesen; 2012 Jan; 74(1):23-8. PubMed ID: 21154203
[TBL] [Abstract][Full Text] [Related]
38. The diffusion of generics after patent expiry in Germany.
Fischer KE; Stargardt T
Eur J Health Econ; 2016 Nov; 17(8):1027-1040. PubMed ID: 26573841
[TBL] [Abstract][Full Text] [Related]
39. Price control as a strategy for pharmaceutical cost containment - what has been achieved in Norway in the period 1994-2004?
Håkonsen H; Horn AM; Toverud EL
Health Policy; 2009 May; 90(2-3):277-85. PubMed ID: 19042052
[TBL] [Abstract][Full Text] [Related]
40. Understanding long-listed pharmaceutical products without competition in South Korea: policy implications in managing generic entrants and pharmaceutical expenditures.
Son KB
Expert Rev Pharmacoecon Outcomes Res; 2022 Jul; 22(5):815-822. PubMed ID: 33765402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
